China approves market entry of self-developed COVID vaccine

The drug, developed by the Beijing Institute of Biological Products and Sinopharm, has received approval from the National Administration of Medical Products.

Chinese authorities have issued a permit for the limited commercial use of the first patented COVID-19 vaccine. On Thursday, December 31, Xinhua reported.

“The vaccine, which has received approval from the National Medical Products Administration, has been developed by the Beijing Institute of Biological Products, affiliated with Sinopharm,” the report says.

It is observed that the provisional results of the third phase of clinical trials of this vaccine demonstrated its effectiveness against COVID-19 at the level of 79.34%, which complies with the WHO standards.

The day before, it was also reported that clinical trials of the vaccine were conducted in different countries around the world. The drug was found to be safe.

The first country to officially approve this vaccine was the UAE, where vaccination with this drug has already begun. Furthermore, this drug was approved by the Bahraini authorities.

News of Correspondent.net on Telegram. Subscribe to our channel https://t.me/korrespondentnet